PE20161325A1 - L-asparaginasa tratada con peg - Google Patents
L-asparaginasa tratada con pegInfo
- Publication number
- PE20161325A1 PE20161325A1 PE2016001555A PE2016001555A PE20161325A1 PE 20161325 A1 PE20161325 A1 PE 20161325A1 PE 2016001555 A PE2016001555 A PE 2016001555A PE 2016001555 A PE2016001555 A PE 2016001555A PE 20161325 A1 PE20161325 A1 PE 20161325A1
- Authority
- PE
- Peru
- Prior art keywords
- peg
- asp
- conjugate
- polyethylene glycol
- asparaginase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se refiere a un conjugado que comprende: i) L-asparaginasa de Erwinia chrysanthemi que comprende la secuencia de aminoacidos de SEQ ID NO:1; y ii) polietilenglicol (PEG) que tiene un peso molecular de 2000 Da a 5000 Da. Dicho conjugado tiene la formula: Asp-[NH-CO(CH2)x-CO-NH-PEG]n, donde: Asp es L-asparaginasa, PEG es un grupo polietilenglicol tal como monometoxi-polietilenglicol, n es un numero que representa 40% al 100% de grupos amino accesibles en la Asp, x es 1 a 8. Tambien se refiere a una composicion farmaceutica. Dicho conjugado es util en el tratamiento de cancer tal como la leucemia linfoblastica aguda (ALL)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22332009P | 2009-07-06 | 2009-07-06 | |
PCT/EP2010/054156 WO2011003633A1 (en) | 2009-07-06 | 2010-03-30 | Pegylated l-asparaginase |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20161325A1 true PE20161325A1 (es) | 2016-12-30 |
Family
ID=42232655
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000023A PE20120501A1 (es) | 2009-07-06 | 2010-07-06 | L-asparaginasa tratada con peg |
PE2016001555A PE20161325A1 (es) | 2009-07-06 | 2010-07-06 | L-asparaginasa tratada con peg |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000023A PE20120501A1 (es) | 2009-07-06 | 2010-07-06 | L-asparaginasa tratada con peg |
Country Status (26)
Country | Link |
---|---|
US (6) | US20120100121A1 (es) |
JP (1) | JP6014956B2 (es) |
KR (1) | KR101731999B1 (es) |
CN (1) | CN102573917B (es) |
AU (1) | AU2010270294B2 (es) |
BR (1) | BR112012000367A2 (es) |
CA (1) | CA2767149C (es) |
CO (1) | CO6612174A2 (es) |
DK (1) | DK2451486T4 (es) |
EA (1) | EA021168B1 (es) |
ES (1) | ES2636476T5 (es) |
FI (1) | FI2451486T4 (es) |
HK (1) | HK1173092A1 (es) |
HU (1) | HUE035771T2 (es) |
IL (1) | IL217392A (es) |
IN (1) | IN2012DN00958A (es) |
LT (1) | LT2451486T (es) |
MA (1) | MA33503B1 (es) |
MX (1) | MX2012000424A (es) |
MY (1) | MY180758A (es) |
NZ (1) | NZ597912A (es) |
PE (2) | PE20120501A1 (es) |
PT (1) | PT2451486T (es) |
SG (1) | SG176984A1 (es) |
UA (1) | UA104634C2 (es) |
WO (2) | WO2011003633A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE531779C2 (sv) * | 2007-11-26 | 2009-08-04 | Promimic Ab | Framställning av kalciumfosfatpartiklar i nanostorlek som pulver eller beläggning via bifunktionella prekursorer |
WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
US20160213759A1 (en) * | 2013-09-10 | 2016-07-28 | Board Of Regents, The University Of Texas System | Therapeutic asparaginases |
CN104046600B (zh) * | 2013-12-30 | 2019-04-05 | 江苏众红生物工程创药研究院有限公司 | 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用 |
BR102014000585B1 (pt) | 2014-01-10 | 2021-01-12 | Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação | l-asparaginase recombinante de zymomonas |
US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
CN105802948B (zh) | 2014-12-29 | 2020-06-09 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 |
WO2017055484A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining the metabolic status of lymphomas |
WO2017151707A1 (en) * | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
DK3463308T3 (da) | 2016-06-01 | 2022-01-31 | Servier Ip Uk Ltd | Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504418B2 (en) * | 2016-11-04 | 2022-11-22 | Crowpierce Technologies, Llc | Endotoxin free asparaginase |
US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
AU2018287145B2 (en) * | 2017-06-21 | 2024-04-18 | Jazz Pharmaceuticals Ireland Limited | Modified L-asparaginase |
EP3418383A1 (en) * | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
EP3700921A4 (en) * | 2017-10-27 | 2021-12-15 | Pfenex Inc. | PROCESS FOR THE PRODUCTION OF RECOMBINANT ERWINIA ASPARAGINASE |
SG11202003614WA (en) | 2017-10-27 | 2020-05-28 | Pfenex Inc | Method for production of recombinant e. coli asparaginase |
CA3083499A1 (en) * | 2017-11-30 | 2019-06-06 | Jazz Pharmaceuticals Ireland Ltd. | Methods of treatment with asparaginase |
WO2019204636A1 (en) * | 2018-04-19 | 2019-10-24 | Kindred Biosciences, Inc. | Variant asparaginase polypeptides for medical use |
WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
US20210308237A1 (en) * | 2019-10-25 | 2021-10-07 | Jazz Pharmaceuticals Ireland Ltd. | Recombinant l-asparaginase |
KR102269634B1 (ko) * | 2019-10-31 | 2021-06-25 | 대상 주식회사 | ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주 |
US20220227805A1 (en) | 2020-12-23 | 2022-07-21 | Jazz Pharmaceuticals Ireland Ltd. | Methods of purifying charge-shielded fusion proteins |
WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
WO2024008659A1 (en) | 2022-07-04 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma |
WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
GB9017002D0 (en) | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5776746A (en) | 1996-05-01 | 1998-07-07 | Genitope Corporation | Gene amplification methods |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US20020065397A1 (en) | 2000-10-12 | 2002-05-30 | Joseph Roberts | Protecting therapeutic compositions from host-mediated inactivation |
US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
AU2002332371A1 (en) * | 2001-08-22 | 2003-03-10 | Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha | Recombinant l-asparaginase less thanigreater thanerwinia caratovoraless than/igreater than |
US7803777B2 (en) | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US7985548B2 (en) | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
WO2007123006A1 (ja) | 2006-04-21 | 2007-11-01 | Konica Minolta Holdings, Inc. | ガスバリアフィルム、有機エレクトロルミネッセンス用樹脂基材、それを用いた有機エレクトロルミネッセンス素子及びガスバリアフィルムの製造方法 |
CN101641439B (zh) * | 2007-03-09 | 2016-05-25 | 诺维信公司 | 天冬酰胺酶 |
WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
-
2010
- 2010-03-30 WO PCT/EP2010/054156 patent/WO2011003633A1/en active Application Filing
- 2010-07-06 AU AU2010270294A patent/AU2010270294B2/en active Active
- 2010-07-06 NZ NZ597912A patent/NZ597912A/en unknown
- 2010-07-06 BR BR112012000367A patent/BR112012000367A2/pt not_active Application Discontinuation
- 2010-07-06 PT PT107301707T patent/PT2451486T/pt unknown
- 2010-07-06 JP JP2012518956A patent/JP6014956B2/ja active Active
- 2010-07-06 CA CA2767149A patent/CA2767149C/en active Active
- 2010-07-06 UA UAA201201135A patent/UA104634C2/ru unknown
- 2010-07-06 PE PE2012000023A patent/PE20120501A1/es not_active Application Discontinuation
- 2010-07-06 PE PE2016001555A patent/PE20161325A1/es unknown
- 2010-07-06 HU HUE10730170A patent/HUE035771T2/en unknown
- 2010-07-06 FI FIEP10730170.7T patent/FI2451486T4/fi active
- 2010-07-06 WO PCT/EP2010/059599 patent/WO2011003886A1/en active Application Filing
- 2010-07-06 EA EA201270134A patent/EA021168B1/ru not_active IP Right Cessation
- 2010-07-06 SG SG2011096013A patent/SG176984A1/en unknown
- 2010-07-06 MY MYPI2012000054A patent/MY180758A/en unknown
- 2010-07-06 DK DK10730170.7T patent/DK2451486T4/da active
- 2010-07-06 LT LTEP10730170.7T patent/LT2451486T/lt unknown
- 2010-07-06 MA MA34598A patent/MA33503B1/fr unknown
- 2010-07-06 CN CN201080030392.6A patent/CN102573917B/zh active Active
- 2010-07-06 ES ES10730170T patent/ES2636476T5/es active Active
- 2010-07-06 KR KR1020127003202A patent/KR101731999B1/ko active IP Right Grant
- 2010-07-06 US US13/382,276 patent/US20120100121A1/en not_active Abandoned
- 2010-07-06 MX MX2012000424A patent/MX2012000424A/es active IP Right Grant
-
2012
- 2012-01-05 IL IL217392A patent/IL217392A/en active IP Right Grant
- 2012-02-02 IN IN958DEN2012 patent/IN2012DN00958A/en unknown
- 2012-02-06 CO CO12020409A patent/CO6612174A2/es unknown
-
2013
- 2013-01-11 HK HK13100524.0A patent/HK1173092A1/xx unknown
-
2015
- 2015-08-05 US US14/819,305 patent/US9920311B2/en not_active Ceased
-
2018
- 2018-02-01 US US15/886,216 patent/US20180346900A1/en not_active Abandoned
-
2020
- 2020-03-18 US US16/822,764 patent/USRE49736E1/en active Active
- 2020-05-18 US US16/877,324 patent/US11046946B2/en active Active
-
2021
- 2021-06-03 US US17/338,508 patent/US20210348151A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20161325A1 (es) | L-asparaginasa tratada con peg | |
AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
BR112013031262A2 (pt) | "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica". | |
HRP20191852T1 (hr) | Polipeptidi | |
CY1113949T1 (el) | Αντιιικη συνθεση, η οποια περιεχει εναν θειικο πολυσακχαριτη: ι-καρραγενανη | |
AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
RS52845B (en) | TREATMENT PROCEDURES USING GLYCOPEGILATED G-CSF | |
CO6470863A2 (es) | Mutantes fgf21 y usos de los mismos | |
RU2016122168A (ru) | Антисмысловые конъюгаты, направленные на аполипопротеин b | |
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
ES2668926T3 (es) | Composición de ARN para el tratamiento del cáncer pulmonar de células no pequeñas (NSCLC) | |
CY1115354T1 (el) | Ενωσεις πεγκυλιωμενης ινσουλινης lispro | |
FI3778885T3 (fi) | Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi | |
BR112013011282A2 (pt) | formulações baseadas em ácido hialurônico | |
AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
NZ607069A (en) | Modified relaxin polypeptides and their uses | |
IN2014DN03325A (es) | ||
CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
BR112013004436A2 (pt) | composições e usos de materiais com atividade microbicida alta e toxicidade baixa | |
UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
HRP20171180T4 (hr) | Pegilirana l-asparaginaza | |
AR054340A1 (es) | Composiciones para el tratamiento del cabello | |
BR112012018691A2 (pt) | "genes que codificam proteínas capazes de aumentar a resistência ao calor de plantas e microorganismos e usos dos mesmos." | |
DE602005026834D1 (de) | Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort |